Terms: = Lymphoma AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Treatment
2409 results:
1. A multicenter, retrospective archive study of radiological and clinical features of alk-positive non-small cell lung cancer patients and crizotinib efficacy.
Kilickap S; Ozturk A; Karadurmus N; Korkmaz T; Yumuk PF; Cicin I; Paydas S; Cilbir E; Sakalar T; Uysal M; Yesil Cinkir H; Uskent N; Demir N; Sakin A; Dursun OU; Aver B; Turhal NS; Keskin S; Tural D; Eralp Y; Bugdayci Basal F; Yasar HA; Sendur MAN; Demirci U; Cubukcu E; Karaagac M; Cakar B; Tatli AM; Yetisyigit T; Urvay S; Gursoy P; Oyan B; Turna ZH; Isikdogan A; Olmez OF; Yazici O; Cabuk D; Seker MM; Unal OU; Meydan N; Okutur SK; Tunali D; Erman M;
Medicine (Baltimore); 2024 May; 103(21):e37972. PubMed ID: 38787994
[TBL] [Abstract] [Full Text] [Related]
2. Two cases of inflammatory myofibroblastic tumor treated with targeted drugs: A case report.
Liu M; Zhu D
Medicine (Baltimore); 2024 May; 103(21):e38136. PubMed ID: 38787978
[TBL] [Abstract] [Full Text] [Related]
3. The outcome of relapsed childhood acute lymphoblastic leukemia after allogeneic hematopoietic stem-cell transplantations: A single-center experience.
Aygüneş U; Karagün BŞ; Şaşmaz I; Antmen AB
Clin Transplant; 2024 May; 38(5):e15366. PubMed ID: 38775798
[TBL] [Abstract] [Full Text] [Related]
4. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell lymphoma Network.
Dreyling M; Doorduijn J; Giné E; Jerkeman M; Walewski J; Hutchings M; Mey U; Riise J; Trneny M; Vergote V; Shpilberg O; Gomes da Silva M; Leppä S; Jiang L; Stilgenbauer S; Kerkhoff A; Jachimowicz RD; Celli M; Hess G; Arcaini L; Visco C; van Meerten T; Wirths S; Zinzani PL; Novak U; Herhaus P; Benedetti F; Sonnevi K; Hanoun C; Hänel M; Dierlamm J; Pott C; Klapper W; Gözel D; Schmidt C; Unterhalt M; Ladetto M; Hoster E
Lancet; 2024 May; 403(10441):2293-2306. PubMed ID: 38705160
[TBL] [Abstract] [Full Text] [Related]
5. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
Haderk F; Chou YT; Cech L; Fernández-Méndez C; Yu J; Olivas V; Meraz IM; Barbosa Rabago D; Kerr DL; Gomez C; Allegakoen DV; Guan J; Shah KN; Herrington KA; Gbenedio OM; Nanjo S; Majidi M; Tamaki W; Pourmoghadam YK; Rotow JK; McCoach CE; Riess JW; Gutkind JS; Tang TT; Post L; Huang B; Santisteban P; Goodarzi H; Bandyopadhyay S; Kuo CJ; Roose JP; Wu W; Blakely CM; Roth JA; Bivona TG
Nat Commun; 2024 May; 15(1):3741. PubMed ID: 38702301
[TBL] [Abstract] [Full Text] [Related]
6. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.
Dai Z; Xu J; Chang F; Zhou W; Ren T; Qiu J; Lu Y; Lu Y
Front Public Health; 2024; 12():1333487. PubMed ID: 38699428
[TBL] [Abstract] [Full Text] [Related]
7. Testing an Intervention to Improve Health Care Worker Well-Being During the COVID-19 Pandemic: A Cluster Randomized Clinical Trial.
Meredith LS; Ahluwalia S; Chen PG; Dong L; Farmer CM; Bouskill KE; Dalton S; Qureshi N; Blagg T; Timmins G; Schulson LB; Huilgol SS; Han B; Williamson S; Watson P; Schnurr PP; Martineau M; Davis K; Cassells A; Tobin JN; Gidengil C
JAMA Netw Open; 2024 Apr; 7(4):e244192. PubMed ID: 38687482
[TBL] [Abstract] [Full Text] [Related]
8. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to alk inhibitors in alk-mutant neuroblastoma.
Pucci P; Lee LC; Han M; Matthews JD; Jahangiri L; Schlederer M; Manners E; Sorby-Adams A; Kaggie J; Trigg RM; Steel C; Hare L; James ER; Prokoph N; Ducray SP; Merkel O; Rifatbegovic F; Luo J; Taschner-Mandl S; Kenner L; Burke GAA; Turner SD
Nat Commun; 2024 Apr; 15(1):3422. PubMed ID: 38653965
[TBL] [Abstract] [Full Text] [Related]
9. Primary cutaneous anaplastic large-cell lymphoma resembling infratemporal space infection: a case report.
Yan X; Ren W; Li S; Zhu Z; Gao L; Zhi K
BMC Oral Health; 2024 Apr; 24(1):470. PubMed ID: 38637781
[TBL] [Abstract] [Full Text] [Related]
10. Navigating resistance to alk inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC.
Gemelli M; Albini A; Catalano G; Incarbone M; Cannone M; Balladore E; Ricotta R; Pelosi G
Expert Rev Anticancer Ther; 2024 Jun; 24(6):347-361. PubMed ID: 38630549
[TBL] [Abstract] [Full Text] [Related]
11. Reclassification of a spindle cell sarcoma after identification of a tfg-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.
Lim JJ; Chen EY; Schaub SK; Wagner MJ
Mol Genet Genomic Med; 2024 Apr; 12(4):e2423. PubMed ID: 38622850
[TBL] [Abstract] [Full Text] [Related]
12. Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with alk fusion: a case report and review of the literature.
Zhang P; Xu J; Wu Q; Qian J; Wang S
Diagn Pathol; 2024 Apr; 19(1):58. PubMed ID: 38616252
[TBL] [Abstract] [Full Text] [Related]
13. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or alk Alterations.
Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
[TBL] [Abstract] [Full Text] [Related]
14. Clinical status and perspective on the application of immunotherapy combined with chemotherapy in advanced non-small cell lung cancer: a review.
Wang T; Zhang L; Cheng Y
Chin Clin Oncol; 2024 Apr; 13(2):26. PubMed ID: 38600808
[TBL] [Abstract] [Full Text] [Related]
15. Anaplastic lymphoma kinase-positive pulmonary inflammatory myofibroblastic tumour: a case report.
Tong D; Chisholm J; Madden B; Ahmed M
J Med Case Rep; 2024 Apr; 18(1):167. PubMed ID: 38594735
[TBL] [Abstract] [Full Text] [Related]
16. [Successful bridging therapy with alectinib prior to allogeneic stem cell transplantation for refractory alk-positive anaplastic large cell lymphoma].
Kono A; Tanaka K; Shimada T; Bando K; Takahata A; Koi S; Yamamoto M; Mori T; Toyota S
Rinsho Ketsueki; 2024; 65(3):158-163. PubMed ID: 38569859
[TBL] [Abstract] [Full Text] [Related]
17. New treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on
Saw SPL; Le X; Hendriks LEL; Remon J
Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e432516. PubMed ID: 38560815
[TBL] [Abstract] [Full Text] [Related]
18. A pragmatic guide for management of adverse events associated with lorlatinib.
Liu G; Mazieres J; Stratmann J; Ou SI; Mok T; Grizzard M; Goto Y; Felip E; Solomon BJ; Bauer TM
Lung Cancer; 2024 May; 191():107535. PubMed ID: 38554546
[TBL] [Abstract] [Full Text] [Related]
19. Evidence-Based Recommendations for Education Provided to Patients and Families Regarding the Adverse Events of alk and MEK Inhibitors: A Systematic Review From the Children's Oncology Group.
Fisher B; Meyer A; Brown A; Conway Keller M; McKeown T; Tiller J; Saylor KM; Duffy EA
J Pediatr Hematol Oncol Nurs; 2024; 41(2):114-128. PubMed ID: 38549368
[No Abstract] [Full Text] [Related]
20. Concurrent inhibition of alk and SRC kinases disrupts the alk lung tumor cell proteome.
Diaz-Jimenez A; Ramos M; Helm B; Chocarro S; Frey DL; Agrawal S; Somogyi K; Klingmüller U; Lu J; Sotillo R
Drug Resist Updat; 2024 May; 74():101081. PubMed ID: 38521003
[TBL] [Abstract] [Full Text] [Related]
[Next]
